Galderma Group AG (GALD) Price & Analysis

Compare

12 Followers

GALD Stock Chart & Stats

CHF162.00

-CHF8.02(-7.15%)

At close: Mar 06 4:00 PM EST

CHF162.00

-CHF8.02(-7.15%)

Day’s Range― - ―

52-Week RangeCHF72.70 - CHF170.10

Previous CloseN/A

Volume230.69K

Average Volume (3M)337.59K

Market Cap

CHF38.04B

Enterprise ValueCHF29.23B

Total Cash (Recent Filing)CHF458.00M

Total Debt (Recent Filing)CHF2.85B

Price to Earnings (P/E)117.2

Beta0.90

Next Earnings

Mar 05, 2026

EPS Estimate

1.19

Next Dividend Ex-DateN/A

Dividend Yield0.09%

Share Statistics

EPS (TTM)1.10

Shares Outstanding237,897,630

10 Day Avg. Volume210,266

30 Day Avg. Volume337,589

Financial Highlights & Ratios

PEG Ratio-0.21

Price to Book (P/B)3.38

Price to Sales (P/S)5.93

P/FCF Ratio123.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF162.00

Price Target Upside0.00%

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceGalderma Group AG's third-quarter sales grew by 21%, outperforming consensus expectations by 4%.

Product LaunchExpected continued acceleration of growth from launches of Nemluvio and Relfydess, as well as from the introduction of 4 new differentiated fillers into the US market.

Strategic InvestmentL'Oreal to increase its stake in Galderma to 20%, with Galderma to consider nominating two board members from L'Oreal, likely to further its understanding of the business and run earnings through its P&L.

Bears Say

Market UncertaintyTrump announced the intention to impose a 100% tariff on imports of branded or patented drugs, adding uncertainty to the market.

Prescription VolumesThe US Labor Day holiday adversely impacted new patient starts, affecting prescription volumes.

Sales Projection ConcernsThere is increased caution around Injectable Aesthetics, which might impact sales projections.

Galderma Group AG News

Galderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections

Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG and increased the price...

7d ago

Strategic Partnership and Stake Increase Drive Positive Outlook for Galderma: Buy Recommendation

Jefferies analyst Benjamin Jackson CFA has maintained their bullish stance on GALD stock, giving a Buy rating today....

11d ago

Galderma Group AG: Promising Growth Outlook and Strategic Expansion Drive Buy Rating

Analyst Benjamin Jackson CFA of Jefferies maintained a Buy rating on Galderma Group AG, retaining the price target...

1M ago

Galderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating

Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG and keeping the price...

2M ago

Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook

Analyst Thibault Boutherin from Morgan Stanley maintained a Hold rating on Galderma Group AG and keeping the price...

2M ago

Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating

Galderma Group AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin Jackson...

2M ago

Galderma Group AG: Buy Rating Affirmed Amid Tariff Challenges and Growth Prospects

Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG. The associated price...

3M ago

Strong Buy Rating for Galderma Group AG Driven by Nemluvio’s Market Performance and Medical Relevance

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG,...

3M ago

Galderma Group AG: Strong First Half Performance and Upgraded Sales Outlook Justify Buy Rating

Jefferies analyst Benjamin Jackson CFA maintained a Buy rating on Galderma Group AG today and set a price...

5M ago

Positive Outlook for Galderma Group AG Driven by Strong Nemluvio Prescription Growth and Upbeat Sales Forecast

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG,...

5M ago

GALD FAQ

What was Galderma Group AG’s price range in the past 12 months?

Galderma Group AG lowest stock price was CHF72.70 and its highest was CHF170.10 in the past 12 months.

What is Galderma Group AG’s market cap?

Galderma Group AG’s market cap is CHF38.04B.

When is Galderma Group AG’s upcoming earnings report date?

Galderma Group AG’s upcoming earnings report date is Mar 05, 2026 which is in 76 days.

How were Galderma Group AG’s earnings last quarter?

Galderma Group AG released its earnings results on Jul 24, 2025. The company reported CHF1.105 earnings per share for the quarter, beating the consensus estimate of CHF0.926 by CHF0.179.

Is Galderma Group AG overvalued?

According to Wall Street analysts Galderma Group AG’s price is currently same. Get more investment ideas with TipRanks Premium

Does Galderma Group AG pay dividends?

Galderma Group AG pays a Notavailable dividend of CHF0.15 which represents an annual dividend yield of 0.09%. See more information on Galderma Group AG dividends here

What is Galderma Group AG’s EPS estimate?

Galderma Group AG’s EPS estimate is 1.19.

How many shares outstanding does Galderma Group AG have?

Galderma Group AG has 237,897,630 shares outstanding.

What happened to Galderma Group AG’s price movement after its last earnings report?

Galderma Group AG reported an EPS of CHF1.105 in its last earnings report, beating expectations of CHF0.926. Following the earnings report the stock price went up 7.575%.

Which hedge fund is a major shareholder of Galderma Group AG?

Currently, no hedge funds are holding shares in CH:GALD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Galderma Group AG

Galderma Group AG is a global dermatology company headquartered in Switzerland, specializing in the development and commercialization of innovative medical solutions for skin health. The company operates primarily in the fields of medical dermatology, aesthetic dermatology, and consumer skin care. Galderma's core products include prescription medications for various skin conditions, aesthetic treatments such as dermal fillers and botulinum toxin, and a range of over-the-counter skin care products designed to address diverse skin concerns.

Galderma Group AG (GALD) Earnings & Revenues

Historic Earnings Reports

GALD Stock 12 Month Forecast

Average Price Target

CHF162.00

▲(0.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"94":"CHF94","191":"CHF191","118.25":"CHF118.3","142.5":"CHF142.5","166.75":"CHF166.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF190.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF162.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF135.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[94,118.25,142.5,166.75,191],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,158.1,160.55384615384614,163.0076923076923,165.46153846153845,167.91538461538462,170.36923076923077,172.8230769230769,175.27692307692308,177.73076923076923,180.18461538461537,182.63846153846154,185.09230769230768,187.54615384615386,{"y":190,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,158.1,158.4,158.7,159,159.29999999999998,159.6,159.9,160.2,160.5,160.8,161.1,161.4,161.7,{"y":162,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,158.1,156.3230769230769,154.54615384615383,152.76923076923077,150.9923076923077,149.2153846153846,147.43846153846152,145.66153846153847,143.8846153846154,142.1076923076923,140.33076923076922,138.55384615384617,136.77692307692308,{"y":135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.47,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":100.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >